{"analyses":[{"ciLowerLimit":"-37.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-21.11","groupDescription":"Comparison of treatments were calculated.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Difference","paramValue":"-29.31","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-39.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-23.22","groupDescription":"Comparison of treatments were calculated.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Difference","paramValue":"-31.39","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1"},{"groupId":"OG001","value":"65.2"}]}],"title":"mRECIST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5"},{"groupId":"OG001","value":"65.7"}]}],"title":"RECIST 1.1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"379"}],"units":"Participants"}],"description":"Disease control rate (DCR) was defined as the percentage of subjects whose best response was CR (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), PR (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or stable disease (SD) (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST and RECIST 1.1 criteria. SD had to be maintained for at least 6 weeks from the first demonstration of that rating.","groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"OG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"OG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of subjects"}